Cemiplimab vs best care after chemo for advanced penile cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a maintenance drug called cemiplimab (an immunotherapy) can help keep your penile cancer from growing after you've finished platinum-based chemotherapy. It's a randomized study, so half the participants get cemiplimab and the other half get the best standard care, so doctors can compare which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and at least 18 years old.
- You have advanced or recurrent penile cancer that cannot be cured with surgery or radiation.
- You have completed 4 to 6 cycles of platinum-based chemotherapy and your cancer is stable or has shrunk.
- You have not had immunotherapy before (like PD-1 or CTLA-4 inhibitors).
- You do not have a major autoimmune disease requiring strong immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
This trial tests a combination of chemotherapy drugs (paclitaxel, ifosfamide, cisplatin) and an immunotherapy drug (triplizumab) given before surgery for locally advanced penile cancer. The goal is to shrink the tumor and improve outcomes.
This trial tests if the immunotherapy drug cemiplimab can help keep advanced or recurrent vulvar cancer from growing after initial chemotherapy. Patients who have finished 4-6 cycles of platinum chemo without their cancer getting worse may be eligible.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This study tests a combination of an immunotherapy drug (cemiplimab) plus chemotherapy for advanced squamous non-small cell lung cancer. Researchers want to see if this treatment works better in people whose tumors have a certain enzyme level.
Hear when a new Penile Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.